<DOC>
	<DOCNO>NCT01471717</DOCNO>
	<brief_summary>This study design evaluate potential pharmacokinetic drug-drug interaction INX-08189 Victrelis , Direct Acting Antiviral ( DAA ) .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics Safety INX-08189 Administered With VictrelisTM Healthy Subjects</brief_title>
	<detailed_description>This single-center , randomize , placebo-controlled study thirty-two 18 55 year old , male female , healthy adult volunteer . Primary Objectives : Pharmacokinetic - To characterize pharmacokinetic ( PK ) profile INX-08189 INX-08032 INX-08189 dose alone compare dosed combination Victrelis - To characterize PK profile Victrelis dose alone compare dosed combination INX-08189 Safety - To evaluate safety INX-08189 Victrelis dose alone dose combination</detailed_description>
	<criteria>Subjects must meet follow criterion Screening Visit ( Visit1 ) , order eligible study drug administration Study Day 0 ( Visit 3 ) : 1 . Must healthy male female 18 55 year age ( inclusive ) body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) , weigh â‰¥ 50 kg time sign informed consent ; 2 . Capable give write informed consent include compliance requirement restriction list consent form . Signed informed consent must file prior screening procedure ; 3 . Subject able understand comply protocol requirement , instruction restriction ; 4 . Must nontobacco user least 3 month prior selection ; 5 . Healthy basis physical examination , medical history , vital sign , electrocardiogram clinical laboratory test screen ; 6 . Women must postmenopausal least 2 year surgically sterile complete hysterectomy bilateral oophorectomy , pregnant breastfeeding ; 7 . Male subject , surgically sterile vasectomy , must agree use double barrier method birth control , , condom plus spermicidal agent ( foam/gel/film/cream/suppository ) . This criterion must follow time first dose study medication 30 day last dose medication . Male subject donate sperm study 3 month receive last dose study drug . Subjects must NOT meet follow criterion Screening Visit ( Visit1 ) , order eligible study drug administration Study Day 0 ( Visit 3 ) : 1 . Infection Hepatitis A , B C Virus ; 2 . Infection Human Immunodeficiency Virus ( HIV ) ; 3 . History current medical condition could impact safety participant study ; 4 . Current active underlying gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease ; 5 . Clinically significant abnormality centrally read ECG ; 6 . Currently significant diarrhea , gastric stasis , constipation investigator 's opinion could influence drug absorption bioavailability ; 7 . Safety laboratory abnormality screen clinically significant , absolute neutrophil count &lt; 1800 cells/mm3 , platelet count &lt; 130,000 cells/mm3 , hemoglobin &lt; 12 g/dl woman &lt; 13 g/dl men ; 8 . Women child bear potential ; 9 . Pregnant breastfeeding ; 10 . Current abuse alcohol illicit drug , history alcohol illicit drug abuse within precede two year ; 11 . A positive urine drug test screening ; 12 . Consumption 2 unit alcoholic beverage per day 14 unit per week ( 1 unit alcohol equal 1 glass beer , 1 glass wine , 25ml shot 40 % spirit ) , consumption alcohol 72 hour study medication intake , consumption average five 240 ml serving coffee caffeinated beverage per day ; 13 . Use chronic prescription medication within 3 month , acute prescription medication within 14 day , systemic overthecounter ( OTC ) medication , include vitamin , within 7 day start study ; 14 . Received investigational drug vaccine within 30 day 5 half life , whichever longer , receipt small molecule 90 day 5 half life , whichever longer , receipt large biological molecule prior Study Day 0 , use investigational medical device within 30 day prior Study Day 0 , participate previously study INX08189 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>PK</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>INX08189</keyword>
	<keyword>Victrelis</keyword>
	<keyword>Inhibitex</keyword>
</DOC>